Research peptide
Semax
Semax is a research peptide indexed in the PeptiBrief evidence database. It has a defined amino-acid sequence in this dossier.
- Sequence
- MEHFPGP
Evidence confidence
Human
3/5
Multiple human studies
2 citations
Animal
4/5
Substantial animal evidence
4 citations
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
2 citations
Claimed uses
- Limited human
- Human (russia)
- Limited
- Insufficient
- Insufficient
Mechanisms
- Upregulation of BDNF and NGF
- Modulation of dopamine and serotonin systems
- Melanocortin and neurotrophic signalling
- Neuroplasticity
Safety notes
Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.
Regulation
- Regulatory and marketing status vary by jurisdiction. It is not generally licensed as a medicine in the United States or United Kingdom.
- Not approved for general wellness or performance use unless a specific regulated product and indication exists.
References
- Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats · 2020
- The efficacy of Semax in treatment of patients at different stages of ischemic stroke · 2018
- Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats · 2017
- The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia · 2014
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia · 2010
- Effectiveness of Semax in the acute period of hemispheric ischemic stroke · 1997
Last reviewed
12 July 2026